Filing Details

Accession Number:
0000921895-21-001455
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-21 16:19:09
Reporting Period:
2021-05-19
Accepted Time:
2021-05-21 16:19:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1123494 Harvard Bioscience Inc HBIO Laboratory Analytical Instruments (3826) 043306140
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1400121 W James Green C/O Harvard Bioscience, Inc.
84 October Hill Road
Holliston MA 01746
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-19 39,188 $2.63 2,318,966 No 4 M Direct
Common Stock Disposition 2021-05-19 39,188 $7.17 2,279,778 No 4 S Direct
Common Stock Acquisiton 2021-05-20 14,876 $2.63 2,294,654 No 4 M Direct
Common Stock Disposition 2021-05-20 14,876 $7.03 2,279,778 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2021-05-19 39,188 $0.00 39,188 $2.63
Common Stock Stock option (right to buy) Disposition 2021-05-20 14,876 $0.00 14,876 $2.63
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
391,878 2027-06-11 No 4 M Direct
377,002 2027-06-11 No 4 M Direct
Footnotes
  1. Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 685,234 shares of common stock beneficially owned by the Reporting Person.
  2. This transaction was executed in multiple trades at prices ranging from $7.07 to $7.26, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. Includes (a) the shares and awards described in footnote (1) above, less (b) the disposition of shares reported in footnote (2) above.
  4. Includes (a) the shares and awards described in footnote (3) above, plus (b) the acquisition of 14,876 shares of common stock pursuant to the exercise of stock options as reported on this Form 4.
  5. This transaction was executed in multiple trades at prices ranging from $7.02 to $7.05, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. Includes (a) the shares and awards described in footnote (4) above, less (b) the disposition of shares reported in footnote (5) above.
  7. The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023.